The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
We are building an AI-native operating system for pharma sales and distribution
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
Pan-India multidisciplinary program aims to improve coordinated care for patients with chronic kidney disease and heart failure
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
Subscribe To Our Newsletter & Stay Updated
